Introduction {#Sec1}
============

The GM2 gangliosidoses, Tay-Sachs (TSD) and Sandhoff (SD) diseases, are neurodegenerative disorders, caused by a deficiency of the lysosomal enzyme beta- hexosaminidase A (Hex A). The deficiency causes accumulation of GM2 ganglioside particularly in neurons where the rate of ganglioside synthesis is the highest, leading to progressive neurodegeneration. Although the incidence of TSD and SD is very low (1 in 320,000 for TSD and even less frequent for SD \[[@CR1]\]) there are common mutations in ethnic populations that make it more frequent. In the Ashkenazi Jewish population, the disease incidence of infantile TSD is about 1 in every 3500 newborns. Similarly, there is a common mutation (*HEXA*, p.GLY269SER) in the eastern European population that accounts for many of the individuals with late onset TSD \[[@CR2]\]. In contrast to infantile TSD or SD disease the late-onset forms have symptom onset in adolescence or early adulthood, with ataxia, selective and progressive muscular atrophy leading to increased falls and difficulty rising from a chair or the floor, and for TSD patients, dysarthria. The heterogeneity of the disease may also result in the misdiagnosing of older adults who have the disease, and a history of neuronal symptoms, through conflation with the clinical indications of other neurodegenerative disorders \[[@CR3]\]. SD patients may often have tingling, numbness or pain in their hands and feet as a presenting sign.

There is currently no cure for TSD or SD. Research is focused on increasing HexA activity by enzyme replacement therapy where the blood brain barrier has been a formidable obstacle; by substrate reduction of ganglioside precursors using small molecules; or by gene delivery \[[@CR4], [@CR5]\]. As new treatment options emerge, it is imperative to identify and validate appropriate outcome measures by which to evaluate potential therapeutic effects.

We believe that these measures should include patient-reported outcomes, to provide the patient's perspective and give them a voice in their own health care \[[@CR6]\]. The development of smartphone applications has made it possible to collect this information easily and often \[[@CR7]\]. In addition, wearable devices can continuously measure the quality and quantity of physical activity \[[@CR8], [@CR9]\], providing valuable information on motor function.

The aim of this study was to assess the feasibility of using digital health technology to monitor GM2 patients remotely between hospital visits. The technology included a wearable device and a smartphone application to record patient-reported outcomes. This proof-of-concept study also focused on capturing patient feedback on use of the technology and exploring the outcome data it can provide. We plan to extend use of the technology to validate outcome measures that monitor disease progression, measure the effects of therapeutic intervention, and solicit further patient feedback on the impact of the disease on their activities of daily living.

Results {#Sec2}
=======

Eight consenting patients took part in the study and remained engaged for its duration. Age ranged from 28 to 61 years (44 ± 11), with three men and five women.

Laboratory and clinical results measured by clinical evaluation over the 6-month course of the study can be seen in Table [1](#Tab1){ref-type="table"}. There were no statistically significant differences between baseline and month six in any of the measures. Table 1Laboratory and clinical data at baseline and six months (mean ± standard deviation) and statistical significance resultsBaselineMonth 6***Wilcoxon p-value***6MWT (meters)316.88 ± 123.26345.50 ± 117.680.11BARS score9.75 ± 6.0910.06 ± 6.960.59Neuroglyphics Off Target-dominant (%)19.00 ± 14.1116.62 ± 10.910.69Neuroglyphics Off Target- Nd (%)21.19 ± 13.9917.77 ± 11.650.47BARS Upper score2.63 ± 2.222.75 ± 2.840.799HP Dom Avg (sec)28.83 ± 8.2327.22 ± 7.840.389HP Dom z-score (sec)4.35 ± 2.774.04 ± 2.770.389HP Nd Avg (sec)30.89 ± 15.8829.84 ± 11.410.789HP Nd z-score (sec)4.71 ± 5.395.05 ± 4.961GAITRite data:Cadence (steps/min)94.33 ± 18.8699.95 ± 13.880.15Velocity (cm/sec)97.86 ± 34.08108.59 ± 33.610.15Step Length (cm)60.10 ± 12.7463.68 ± 14.620.38Step Width (cm)11.72 ± 3.7711.53 ± 3.460.55Step Time (sec)0.67 ± 0.150.61 ± 0.090.11*Avg* Average, *BARS* Brief Ataxia Rating Scale, *cm* Centimetres, *DOM* Dominate *min* Minute, *6MWT* 6-min walk test, *Nd* Non-dominant, *sec* Seconds, *9HP* 9-hole peg test -- a brief, standardized and quantitative test of upper extremity (hand and arm) function z-score: calculated by converting raw into a common metric

Adherence {#Sec3}
---------

Adherence to wearing the device ranged from 35 to 96% in terms of each individual patient over the 6-month period of the study. The median cohort adherence rate was 84%. Wearable usage decreased slightly from 3 months to 6 months primarily due to decreased usage over a holiday period and the coinciding battery life limits. The mean (standard deviation) number of daily steps for the cohort of eight patients was 7253.2 (490.0) with a median of 6526.9 steps. Complete data are seen in Table [2](#Tab2){ref-type="table"}. Table 2Individual Patient Wearable Data and adherence rates (complete data)Patient Number001002003004005006007008**Wearable dataTotal Number of Days**186186186186185185185185**Total Number of Days Active on Wearable**15717965157164122121164**Average Daily Steps**10,147.7 ± 15096432.8 ± 290.794122.1 ± 318.84560.6 ± 208.2112,424.6 ± 323.139342.7 ± 178.85909.6 ± 689.34041.7 ± 196.6**Adherence rate (%)**8496358489666589**Patient Reported outcomes (PROs)Adherence rate (%)**9795918291756396*SD* standard deviation

For the wearable data, the median adherence rate i.e. calculated when the patient completed a minimum of 8 × 30-min epochs of data, was 91% (range: 63--97%). All patients gave at least two responses to each PRO over the 6-month period, but adherence to the PROs was variable by patient and month and overall tended to decrease towards the end of the study (see Fig. [1](#Fig1){ref-type="fig"}). Fig. 1Individual Patient Adherence to Completion of PRO Data

Wearable data {#Sec4}
-------------

The average steps per epoch over a 24 h Period (from midnight to midnight) is illustrated in Fig. [2](#Fig2){ref-type="fig"}. On average, less activity was recorded between midnight and 7 am, consistent with average sleep patterns. Patient NIH-APT-006 who reported activity above 250 average steps per epoch at night worked night shifts. Fig. 2Average number of steps per 30-min epoch over a 24-h period

Three wearable metrics were calculated (described in more detail in the Methods section): the average daily maximum (ADM), average daily steps (ADS), and average daily steps per 30-min epoch (ADE). Cohort analysis of ADM, ADS, ADE is presented in Table [3](#Tab3){ref-type="table"}. No statistically significant changes were observed between baseline and month six. Table 3Cohort averages and statistical significance results for the wearable metricsMean (Median)M0-M1M1-M2M2-M3M3-M4M4-M5M5-M6Overall Cohort Mean (Median)\
\[range\]***Wilcoxon p-value*ADM**1171.6 (1063.2)1183.2 (954.1)952.0 (893.7)1094.1 (935.9)1011.3 (1065.6)943.5 (811.1)1059.6 (962.3) \[684 to 1625\]0.10**ADS**6902.7 (6452.9)6850.6 (6867.9)7825.7 (7068.2)8431.5 (6525.0)7317.2 (5955.8)6346.6 (4971.1)7253.2 (6526.9) \[2532 to 16,315\]0.51**ADE**288.9 (240.8)264.2 (208.3)272.8 (236.0)277.8 (238.4)260.0 (281.8)259.5 (246.3)270.6 (235.8) \[125 to 475\]0.80*ADM* Average daily maximum, *ADS* Average daily steps, *ADE* Average daily steps per 30-min epoch. *M* month

Clinical event data {#Sec5}
-------------------

Every single patient used the app to record their symptoms (range: 8--79 events reported). In terms of the number of patients who reported each event respectively, seven patients reported a fall/near fall (66 events), and six patients reported choking/coughing (67 events). Other symptoms reported were Tremor (10 events), Other (49 events), and Other Illness (72 events).

Other Illness, which covered a broad range of options ("Vomiting", "Headache", "Cold", "Cough" and "Diarrhea"), was the most frequently reported event from the pre-selected options (72 events), while missed college/ work was the least reported event (5 events).

Five patients reported 'Other' events using free text. Of those, health-related responses were hiccups, leg/hip muscle spasm, headache, injuring arm, having an appointment with a physician because of feeling tired, lower back pain, acid reflux, short term memory, fall, migraine, neuropathy to right hip, muscle cramp, incontinence, sharp pain to body parts, numbness/tingling, bone grinding such as in the hip and taking medication such as Ibuprofen and Tylenol.

These self-reported clinical events are of paramount importance not only on their own but also to put context around the objective data of the wearable. In addition, the ability to report in real-time reduces the impact of memory recall on the details provided.

mPRO data {#Sec6}
---------

Table [4](#Tab4){ref-type="table"} shows the Rosenberg Self Esteem scale, which is a widely used and validated self-esteem measure with a scale of 0 to 30, with a score less than 15 indicating potential problematic low self-esteem. Our cohort average ranged from 14.4 to 15.4 suggesting that this cohort are on the low side of self-esteem \[[@CR10]\]. PedsQL fatigue scores ranged from 46.5 to 61.1 on a scale of 0 to 100, indicating fatigue in this cohort \[[@CR11]\]. Self-reported "Impact on Family" was scored higher than "Impact of Disease". Table 4mPRO and QoL scale results across the 6-month period with overall cohort averages and statistical significanceMean (Median)\
\[min-max\]M0M1M2M3M4M5M6Overall Cohort***Wilcoxon p-value**Hollander p-value***Reference rangeTremor impact0.0 (0.0)\[0.00--0.00\]0.4 (0.0)\[0.00--1.00\]0.8 (0.5)\[0.00--2.00\]1.0 (1.0) \[0.00--2.00\]0.7 (0.5)\[0.00--2.00\]0.9 (1.0)\[0.00--2.00\]1.3 (1.0)\[0.00--2.00\]0.7 (0.5)\[0.00--2.00\]0.050.93750--3Higher score: more tremorDisease Impact4.5 (5.0)\[2.00--7.00\]4.9 (4.5)\[0.00--10.00\]4.1 (4.0)\[1.00--6.00\]5.8 (6.5) \[1.00--10.00\]5.6 (5.0)\[2.00--9.00\]6.1 (5.0)\[3.00--10.00\]5.7 (5.5)\[3.00--9.00\]5.2 (5.0)\[0.00--10.00\]0.2000--19Higher score = higher impactImpact on the family6 (6.0)\[2.00--9.00\]6.1 (6.0)\[4.00--9.00\]5.6 (6.0)\[2.00--8.00\]6.3 (6.0) \[5.00--8.00\]6.3 (6.0)\[5.00--8.00\]6.1 (6.0)\[5.00--8.00\]6.3 (6.5)\[5.00--8.00\]6.1 (6.0)\[2.00--9.00\]0.7900--12Higher score = higher impactWider impact1.3 (0.0)\[0.00--7.00\]1.3 (0.0)\[0.00--7.00\]2.6 (1.0)\[0.00--7.00\]1.2 (0.0) \[0.00--6.00\]1.6 (0.0)\[0.00--7.00\]0.9 (0.0)\[0.00--5.00\]1.8 (1.0)\[0.00--7.00\]1.5 (0.0)\[0.00--7.00\]1.000--14Higher score = higher impactImpact Composite Scale0.27 (0.28)\[0.11--0.40\]0.28 (0.31)\[0.10--0.40\]0.29 (0.27)\[0.08--0.44\]0.32 (0.34) \[0.15--0.45\]0.27 (0.25)\[0.00--0.49\]0.30 (0.29)\[0.21--0.40\]0.31 (0.31)\[0.23--0.40\]0.27 (0.29)\[0.00--0.49\]0.4200--1Higher score = higher impactPerceived Stress17.9 (18.5)\[11.00--26.00\]NA19.6 (21.0)\[7.00--25.00\]NA16.3 (18.0)\[9.00--24.00\]NA20.0 (20)\[12.00--29.00\]18.4 (19.3)\[7.00--29.00\]0.040.87420--40Higher score = higher stressGlobal Self Worth17.0 (17.5)\[12.00--24.00\]NA16.0 (15.5)\[13.00--22.00\]NA17.8 (18.0)\[14.00--22.00\]NA18.1 (18.0)\[14.00--24.00\]17.2 (17.8)\[12.00--24.00\]0.590.50--24Higher score = higher self-worthRosenberg Self Esteem15.0 (15.0)\[11.00--17.00\]NA15.3 (15.5)\[11.00--19.00\]NA14.4 (14.0)\[13.00--16.00\]NA15.4 (15.0)\[13.00--19.00\]15.0 (15.0)\[11.00--19.00\]0.6800--30Higher score = higher self esteemCHU 9D0.87 (0.88)\[0.67--0.96\]NA0.84 (0.83)\[0.66--1.00\]NA0.83 (0.83)\[0.68--0.92\]NA0.83 (0.84)\[0.72--0.95\]0.84 (0.83)\[0.66--1.00\]0.360.4380.33--1Higher score = better healthPedsQL Multi-dimensional Fatigue49.5 (46.5)\[31.94--73.61\]46.5 (43.1)\[27.78--75.00\]46.7 (43.1)\[38.89--66.67\]49.7 (45.8) \[34.72--73.61\]46.6 (45.1)\[29.17--75.00\]50.2 (50.0)\[31.94--83.33\]61.1 (58.3)\[50.00--75.00\]49.6 (45.8)\[27.78--83.33\]0.7300--100Higher score = less fatigue*CHU 9D* Child Health Utility 9D, *M* month

Health care visits data {#Sec7}
-----------------------

Seven out of eight patients used the app to report healthcare visits at least once. Number of Visits responses ranged for each individual patient from 0 to 65 for Healthcare Professional (*n* = 117), 0--2 for General Practitioner (*n* = 4), and 0--3 for Hospital (*n* = 3). Healthcare Professional was the most reported healthcare visit at 117.

Correlations {#Sec8}
------------

Correlations were calculated between the three-wearable metrics (ADM, ADS, ADE), three clinical measures (6-min walk test (6MWT), Brief Ataxia Rating Scale (BARS), and cadence from the GAITRite walking assessment) and the ten mPROs at baseline and at month-6. For clarity, Fig. [3](#Fig3){ref-type="fig"} highlights only results with moderate to strong correlations (coefficients \> 0.6 or \< − 0.6), and *p* \< 0.05 is indicated by an asterisk. Fig. 3Correlations between clinical measures, wearable and mPRO data for baseline (top) and month 6 (bottom). The upper triangles show the positive correlations, and the lower triangles show the negative correlations: the darker the colour, the higher the correlation. Note that the Tremor scale is not included in the baseline correlations, as it was zero for all patients

Some of the wearable metrics are correlated with each other at month 0, with the highest positive correlations between the clinical walking assessments (6MWT and GAITRite cadence; 0.96), and between ADM and ADE (0.83) and the highest negative correlation seen between disease impact (i.e. impact of late onset GM2) and ADS (0.94) which may suggest that higher physical activity measured with the wearable device is linked to better walking performance and lower disease impact. The clinical walking assessments are also negatively correlated with the Impact Scales, but to a lesser extent than the wearable metrics. BARS score does not show any correlation with 6MWT or GAITRite. There were stronger correlations seen at month 6 when compared to month 0 between the three wearable metrics and impact factors. Stronger correlations were seen at month 6 than month zero between the three wearable metrics and impact factors.

Feedback survey {#Sec9}
---------------

A feedback survey was conducted at the end of the study and indicated that all eight patients considered the app to be "valuable" for reporting their symptoms to their doctor in real time, with four patients stating the app to be "very valuable". Overall, 37.5% of patients said they were definitely likely to continue wearing the wristwatch and use the phone app on a long-term basis. A "very good" overall impression was reported by two out of eight patients, one reported their overall impression as "good", and four as "ok". This feedback was instrumental in the redevelopment of the app and the introduction of a new wearable.

Discussion {#Sec10}
==========

This feasibility study demonstrated that utilizing mHealth with wearable technology was well accepted by patients over a six-month natural history study. Adherence to wearing the device remained greater than 65% throughout the six-month period for seven out of eight patients.

Engagement with the app (symptoms and mPROs) was utilized by all patients over the course of the study. In fact, at the end of the study some of the patients chose to continue to use the technology. It was noted that patient 003 had low adherence with respect to the wearable data but high adherence to the PROs. An explanation for this is that this patient experienced issues with the band on her device, which broke. A spare device was also sent to this patient which resulted in data loss.

Engagement with the app for Events indicates its value in patients monitoring their symptoms in real-time. Collecting patient-generated data outside of the hospital setting, for example, during drug development, enables healthcare professionals to capture data remotely on a real-time basis. This not only enables researchers and healthcare professionals to capture disease changes, but also reduces the burden on the healthcare system because fewer hospital-based assessments may be needed, either during a clinical study or for clinical practice. This also means patients benefit from having to attend fewer hospital appointments. The additional value of machine learning /artificial intelligence (ML/AI) provides additional support for the clinical value of the device/app, which can't be implemented by human resources.

The clinical data (Table [1](#Tab1){ref-type="table"}) suggest that the physical ability of the patients in the 6MWT remained the same or slightly improved over the six months. Likewise, all the GAITRite parameters tended to be higher at month six, but the increase was not statistically significant. The BARS assessment remained stable over the duration of the six-month study. This indicates that disease state as measured by these parameters remained stable during this relatively short observation period for a disorder with a documented slow progression.

Figure [2](#Fig2){ref-type="fig"} shows the average steps per epoch over a 24 h period. Measuring such repeated patterns in longitudinal data collection can identify patterns and routines specific to each patient. Specific patterns that arise from commute and work breaks could be identified, and act as indicators of disease progression when things change. Patients with very low-level levels of activity in a month, i.e. engagement with wearing the device, had their data for any month excluded from analysis if the number of active days in that month was less than six days. It should be noted that the specific wearable device used was not able to differentiate between data captured while being worn by the patient or not, so patients with low activity might have had their activity discounted if they had not been active for a total of 8 × 30-min epochs.

The decrease in wearable usage seen during the period from 3 to 6 months is thought to be largely because of decreased usage over the holiday period and the coinciding battery life limits. Several of the patients needed to replace the batteries in the wearable device, therefore losing a few days of data.

Table [3](#Tab3){ref-type="table"} shows that there were no changes in the wearable metrics (defined as ADM, ADS, and ADE), in the six-month period of the study. This is consistent with the hospital-based assessment of 6MWT and GAITRite. As the study started in August and finished in February, the mild decrease noted could be linked to seasonal variation and changes in the weather. The ADS values obtained from patients were are high. This in part may have been as a result of the patients being conscious of the wearable monitoring their ambulatory activity, thus increasing their motivation. Prior studies have shown the use of pedometers to increase the number of steps taken by a range of 2000--2500 per day \[[@CR12]\].

Engagement with the app for Events indicates its value in patients monitoring their symptoms in real-time. The high number of reports of falls/near falls and choking/coughing supports natural history data since these are both disease symptoms known to be associated with disease progression. The limited number of tremor-related events may reflect the fact that tremor's were also reported as part of the weekly mPROs and that this is not a consistent symptom in all patients.

With a small number of patients and a large number of variables, the correlation analysis aims to suggest relationships, rather than provide clear evidence. Figure [3](#Fig3){ref-type="fig"} shows that highly active patients, as measured with the wearable, perform better at the clinical walking tests, and report lower disease impact. As the clinical assessments do not all seem to agree (i.e. ataxia does not show a negative relationship to walking performance), the combination of mPROs and wearable could provide additional information on disease impact. Increased correlation was seen between the wearable metrics and impact scales at month 6 compared to month zero. This was unexpected given that LOTS is a stable disease and there weren't many changes in ADM, ADS or ADE over the 6-month study period. As this was a natural history study with a small sample size, it is not possible to rationalise these observations as the statistics are only indicative.

One of the insights gained through this study was that clinical measures do not always match patient self-perceived disease impact. For example, the patient with the highest reported score of Wider Impact and Tremor mPROs (008) had the third *least* disease impact according to the BARS score. However, the same patient reported the highest number of Events, and the highest number of healthcare visits ("Psychiatrist for physical therapy", "MRI as part of natural history study", "Phlebotomist", "Speech Therapist", "Neurologist", "Psychologist", "Dietician" and "Urologist"). This shows that the self-perceived impact of the disease is an important measure to consider in disease burden and may not correlate with clinical testing. The low perceived self-esteem of patients observed through their responses to the PROs, is expected in this patient population. Low self-esteem, emotional health and psychological issues are highly reported in patients with rare genetic disorders \[Rare Disease UK 2018 -- Living with a rare condition: the effect on mental health\].

As a consequence of the feedback from the patient survey, many improvements have been made, and a new wearable device has been identified which will be integrated into future studies. Additional features will be developed including an integration of video conferencing and secure messaging to enable telemedicine consultations.

Conclusions {#Sec11}
===========

In a highly motivated cohort of patients with a rare disease, mHealth and wearable technology was shown to be useful and feasible for capturing remote, real-time insight into disease burden. It is likely that a longer observation period will yield a clearer understanding of the nuances of disease progression and the individualized impact of disease burden that can be used as outcomes to therapeutic interventions.

Methods {#Sec12}
=======

Patients were recruited at the National Institutes of Health in the USA, as part of an ongoing natural history study (02-HG-0107). All patients who were approached about the study consented to take part. Consenting patients were admitted for a three day stay for clinical assessments at baseline and at the 6-month completion of the trial including the Brief Ataxia Rating Scale (BARS) and subtest, the 6 min walk test (6MWT), neuroglyphics (a digital Archimedes spiral-drawing accuracy rating tool), the 9-hole peg test and GAITRite walking assessment.

All consenting patients downloaded the Aparito app via Google or the App store (Android and iOS respectively) at the baseline visit and this was paired with a 3D accelerometer device to be worn on the wrist. Patients were asked to wear the 3D accelerometer continuously for the six-month duration of the study. The 3D accelerometer wrist-worn device captured data in 30-min epochs and calculated the number of steps taken for that 30-min period. The term 'activity' means patient engagement when wearing the device; activity does not mean physical activity in the context of this study (Fig. [4](#Fig4){ref-type="fig"}). Fig. 4A Million Bluetooth pedometer wearable device was paired with an Aparito app (available on iOS and Android).

Three wearable metrics were computed as defined below: i)The average daily maximum (ADM) is the maximum number of steps per epoch on each active day, averaged over all active days in the month.ii)Average daily steps (ADS) is the total number of steps taken by a patient on active days in a month divided by the number of active days.iii)The average daily steps per epoch (ADE) is calculated as follows. The total number of steps in an active day is divided by the number of active epochs. This is then further averaged over the number of active days in the month.

Patients with very low-level levels of activity in a month had their data for any month excluded from analysis if the number of active days in that month was less than six days.

The patient-facing app captured disease symptoms which patients could access to report any symptom or health-related problem in real-time on the app. The pre-configured health symptoms were already listed in the app as a drop-down menu: Choking / Coughing, Fall / Near Fall, Missed College / Work, Tremor, Other Illness, Other (Note: patients entered their symptoms/problem via free text for this category).

Ten mPROs were pushed to the app at pre-set intervals ranging from 8 to 60 days. The mPROS were the Tremor Impact Scale, Disease Impact Scale, Family Impact Scale, Wider Impact Scale, Impact Composite Scale, Perceived Stress, Global Self-worth, Rosenberg Self Esteem, CHU9D and PedsQL Multi-dimensional Fatigue scale. These are described in the [Appendix](#Sec13){ref-type="sec"}. The different PROs were pushed out at varying schedules as described in Table 13 in the [Appendix](#Sec13){ref-type="sec"}. It should be noted that four patients carried on using the App after the agreed 6-month study period, but these data are not reported in this paper.

Patients also had the ability to record health care appointments in a 'Visits' section, allowing patients to record planned or emergency visits to different health care professionals via the app provided. The pre-configured visits already listed in the app included general practitioner, healthcare professional and hospital. In addition to this, patients had the option to provide further detail of the visit.

All wearable, clinical and mPRO data were tested for overall trends between baseline and month six. The methods used were the Wilcoxon matched pairs test and the Hollander test for bivariate symmetry \[[@CR13]\]. These tests take account of the nonparametric nature of some of the data and the presence of tied data.

Correlation testing was pre-planned before the start of the study. No adjustments of *p*-values for multiple comparisons was made due to the exploratory nature of the study. At both baseline and month six the relationships between wearable data and clinical and mPRO data and within the set of three wearables were tested using the Spearman's rank correlation test. This approach tests between-patient correlation at one time point. Correlations with coefficient ≥ \|0.6\| were considered as moderate to strong relationships \[[@CR14]\].

The rationale for testing all mPRO data against the three wearable metrics was to explore new PROs against the metrics because there are no disease-specific PROs currently available for LOTs. Therefore, the correlation analyses were exploratory.

Adherence for the device was calculated when a minimum of 4 h of data (i.e. 8 × 30-min epochs) were captured for that day. Adherence was calculated as the total number of days active on the device divided by the total number of days in the 6-month study period. Adherence for the PRO responses presented in Table [2](#Tab2){ref-type="table"} was calculated by dividing the total number of actual responses per month by the number of expected responses per month for all PRO surveys over the 6-month period multiplied by 100. The average adherence rate for each month was calculated by dividing the total number of actual responses by the number of patients (i.e. 8 patients) multiplied by 100.

To learn from the experience and to improve on the technical capabilities of the wearable device, patients were asked to answer a questionnaire at the end of the study. The questionnaire comprised five questions.

Appendix {#Sec13}
========

Tremor Impact Scale {#Sec14}
-------------------

This scale, developed specifically for this study as it is a known complication of disease, was available for patients to record tremor in a particular week, and its impact on their ability to perform tasks~~.~~ This PRO has a scale from 0 to 3 for a single domain. The highest total score of 3 'Yes, I had a severe tremor that impeded my ability to perform everyday tasks.' is interpreted as the highest severity of tremors and 0 reflected 'No, I did not have a tremor". The complete range of questions with their possible answers and corresponding quantitative values are shown in Table 5 in [Appendix](#Sec13){ref-type="sec"}. Table 5TremorTremorQuestionPossible AnswerNumerical valueDid you experience a tremor this week?No, I did not have a tremor.0Yes, I had a mild tremor, but it did not interfere with my ability to perform everyday tasks.1Yes, I had a moderate tremor that interfered with my ability to perform everyday tasks.2Yes, I had a severe tremor that impeded my ability to perform everyday tasks.3**Total Score**3

Impact of Late Onset GM2 Scale {#Sec15}
------------------------------

This scale was modified from the Niemann Pick -C Patient/Parent Reported Scale that was developed by the International Niemann-Pick Disease Association for use in their disease registry as an indicator for the impact of disease. The questions asked were the impact of their disease on the ability to walk, coordination, speech, ability to swallow and cognitive abilities. This PRO has a total of 5 domains, with a scale scoring range for each individual domain of 0--3 to 0--5 depending on the domain (Table 6 in [Appendix](#Sec13){ref-type="sec"}). This PRO also has a total score range from 0 to 19, where a high score implies high disease impact on an individual.

Table 6Impact of Late Onset GM2Impact of Late Onset GM2QuestionPossible AnswerNumerical ValueNumerical Value Converted (For composite scale)This section relates to your ability to walk about from place to place. Please select the option that best describes how you are generally.I have no problems walking about00I am clumsy10.2I am unsteady on my feet20.4I can walk but only with assistance, particularly outdoors30.6I normally use a wheelchair outdoors. Inside/at home I move about on my feet but need assistance40.8I cannot walk at all and to get around I always use a wheelchair51This section relates to your ability to coordinate your movements. Please select the option that best describes how you are generally.I have no problems coordinating movement00My movements can be shaky or trembling10.25I have some problems with coordinating movement20.5I have problems with coordinating movement, but can still feed myself30.75I cannot perform any activities independently and need help to do everything41This section relates to your speech. Please select the option that best describes how you are generally.I have no problems with speech00My speech can be difficult to understand10.333My speech is very difficult to understand and really only people who know me very well can understand what I am saying20.667I cannot speak, but can communicate in other ways31This section relates to your ability to swallow. Please select the option that best describes how you are generally.I have no difficulty in swallowing00I chew abnormally10.25I sometimes have difficulty in swallowing, and may occasionally cough while eating or drinking20.5I have difficulty in swallowing every day, frequently coughing or choking on food or drinks30.75My difficulties in swallowing are so severe that I now must be fed by nasogastric tube or gastrostomy.41Do you think your cognitive abilities are impacted by late onset GM2 gangliosidosis? i.e. learning new skills, making decisions, following instructions, focusing your attentionNot at all00A little bit10.333Quite a bit20.667Very much31**Total Score**19

Impact on the family of a late onset GM2 Patient Scale {#Sec16}
------------------------------------------------------

This scale was developed by the International Niemann-Pick Disease Association for use in their disease registry. This PRO allows patients to record how their disease impacted their family. Questions included whether family members had to give up things due to the patient's illness (Table 7 in [Appendix](#Sec13){ref-type="sec"}). This PRO has a total of 4 domains, with an individual domain scoring range of 0--3 for one domain, while the other domains have a negative scoring from 3 to 0, as shown in Table 7 in [Appendix](#Sec13){ref-type="sec"}. This PRO has a total score range from 0 to 12, where a higher total score implies a higher negative impact on family life.

Table 7Impact on the family of a late onset GM2 patientImpact on the family of a late onset GM2 patientQuestionPossible AnswerNumerical valueConverted Value (For composite scale)I don't have much time left over for other family members after caring for myselfStrongly Agree31Agree20.667Disagree10.333Strongly Disagree00Our family gives up things because of my illnessStrongly Agree31Agree20.667Disagree10.333Strongly Disagree00I worry about what will happen in the futureStrongly Agree31Agree20.667Disagree10.333Strongly Disagree00Because of what we have shared we are a closer familyStrongly Agree00Agree10.333Disagree20.667Strongly Disagree31**Total Score**12

Wider Impact scale {#Sec17}
------------------

This scale was also developed by the International Niemann-Pick Disease Association for use in their disease registry. This PRO allows patients to record the wider impact of late onset GM2. The questions asked include the impact on the jobs/school of family members, and visits to emergency rooms due to the illness. A full list of the questions and possible answers can be found in Table 8 in [Appendix](#Sec13){ref-type="sec"}. This PRO has a total of 4 domains, with a domain scoring range of 0--3 and 0--4 which is dependent on the domain being considered. This PRO has a total score range from 0 to 14 where a higher score implies a wider negative impact of the disease.

Table 8Wider impact of late onset GM2 gangliosidosisWider impact of late onset GM2 gangliosidosisQuestionPossible AnswerNumerical valueConverted Numerical Value (For composite scale)Over the past month, did you miss any time from your job or school due to your illness?No00Yes, 1 day10.25Yes, 2 days20.5Yes, 3 or 4 days30.75I have been unable to work/study due to my illness or have changed my working pattern to be able to accommodate my illness41Over the past month, have other family members missed time from their job or school (i.e. college or university) due to your illness?No00Yes, 1 day10.25Yes, 2 days20.5Yes, 3 or 4 days30.75Another family member has changed his/her working pattern to be able to care for me41How many times, during the past month, did you visit the emergency room because of issues relating to your illness?Never001 time10.332--3 times20.66More than 4 times31During the past month, how many appointments have you had with a physician regarding your illness?None001 appointment10.332--3 appointments20.66More than 4 appointments31**Total Score14**

Impact Composite Scale {#Sec18}
----------------------

Impact Composite Scale consists of 3 different impact scales: the Impact of Late onset GM2 (Table 6 in [Appendix](#Sec13){ref-type="sec"}), the Impact on the family of a late onset GM2 patient (Table 7 in [Appendix](#Sec13){ref-type="sec"}), and the Wider Impact (Table 8 in [Appendix](#Sec13){ref-type="sec"}). These were combined using a mean composite scoring system \[[@CR15]\] to have a total score range from 0 to 1 where a higher score implies higher negative impact.

Perceived Stress {#Sec19}
----------------

This scale was taken from the Perceived Stress Scale, a psychological instrument used for measuring the perception of stress \[[@CR16]\]. For this PRO, patients rate specific situations on how stressful they felt. This PRO has a total of 10 domains, with an individual domain scoring range of 0--4, and which also includes negative scoring from 4 to 0. The total scoring range from all domains is 0--40, where a high score implies a high amount of perceived stress. A full list of the questions and possible answers can be found in Table 9 in [Appendix](#Sec13){ref-type="sec"}.

Table 9Perceived StressPerceived StressQuestionPossible AnswerNumerical valueIn the last month, how often have you been upset because of something that happened unexpectedly?Never0Almost Never1Sometimes2Fairly Often3Very Often4In the last month, how often have you felt that you were unable to control the important things in your life?Never0Almost Never1Sometimes2Fairly Often3Very Often4In the last month, how often have you felt nervous and "stressed"?Never0Almost Never1Sometimes2Fairly Often3Very Often4In the last month, how often have you felt confident about your ability to handle your personal problems?Never4Almost Never3Sometimes2Fairly Often1Very Often0In the last month, how often have you felt that things were going your way?Never4Almost Never3Sometimes2Fairly Often1Very Often0In the last month, how often have you found that you could not cope with all the things that you had to do?Never0Almost Never1Sometimes2Fairly Often3Very Often4In the last month, how often have you been able to control irritations in your life?Never4Almost Never3Sometimes2Fairly Often1Very Often0In the last month, how often have you felt that you were on top of things?Never4Almost Never3Sometimes2Fairly Often1Very Often0In the last month, how often have you been angered because of things that were outside of your control?Never0Almost Never1Sometimes2Fairly Often3Very Often4In the last month, how often have you felt difficulties were piling up so high that you could not overcome them?Never0Almost Never1Sometimes2Fairly Often3Very Often4**Total Score**40

Global Self Worth {#Sec20}
-----------------

This PRO scale was modified from the Global Self-Worth Scale \[[@CR17]\], and was developed for patients to rate specific situations stated in the PRO on their self-worth. This PRO has a total of 6 domains, with an individual domain scoring range of 0--4 and which also includes negative scoring from 4 to 0 (Table 10 in [Appendix](#Sec13){ref-type="sec"}). The total scale scoring range from all domains is 0--24, where a higher score implies a higher self-worth.

Table 10Global Self WorthGlobal Self WorthQuestionPossible AnswerNumerical ValueSome people are often unhappy with themselves. BUT Other people are pretty pleased with themselves.'Some people are often unhappy with themselves.' is really true for me.1'Some people are often unhappy with themselves.' is sort of true for me.2'Other people are pretty pleased with themselves.' is sort of true for me3'Other people are pretty pleased with themselves.' is really true for me.4Some people don't like the way they are leading their life. BUT Other people do like the way they are leading their life.'Some people don't like the way they are leading their life.' is really true for me.1'Some people don't like the way they are leading their life.' is sort of true for me.2'Other people do like the way they are leading their life.' is sort of true for me3'Other kids do like the way they are leading their life.' is really true for me.4Some people are happy with themselves as a person. BUT Other people are often not happy with themselves.'Some people are happy with themselves as a person.' is really true for me.4'Some people are happy with themselves as a person.' is sort of true for me.3'Other people are often not happy with themselves.' is sort of true for me.2'Other people are often not happy with themselves.' is really true for me.1Some people like the kind of person they are. But Other people often wish they were someone else.'Some people like the kind of person they are.' is really true for me.4'Some people like the kind of person they are.' is sort of true for me.3'Other people often wish they were someone else.' is sort of true for me.2'Other people often wish they were someone else.' is really true for me.1Some people are very happy being the way they are but other people wish they were different.'Some people are very happy being the way they are.' is really true for me.4'Some people are very happy being the way they are.' is sort of true for me.3'Other people wish they were different.' is sort of true for me.2'Other people wish they were different.' is really true for me.1Some people are not very happy with the way they do a lot of things but other people think the way they do things is fine.'Some people are not very happy with they way they do a lot of things.' is really true for me.1'Some people are not very happy with they way they do a lot of things.' is sort of true for me.2'Other people think the way they do things is fine.' is sort of true for me.3'Other people think the way they do things is fine.' is really true for me.4**Total Score**24

Rosenberg Self-Esteem {#Sec21}
---------------------

This PRO scale was modified from the Global Self-Worth Scale \[[@CR18]\], and was developed for patients to rate specific situations stated in the PRO on their self-esteem. This PRO has a total of 10 domains, with an individual domain scoring range of 0--3 and which also includes negative scoring from 3 to 0 (Table 11 in [Appendix](#Sec13){ref-type="sec"}). The total scale scoring range from all domains is 0--30, where a higher score implies a higher self-esteem.

Table 11Rosenberg Self EsteemRosenberg Self-esteemQuestionPossible AnswerNumerical valueOn the whole, I am satisfied with myself.Strongly Agree3Agree2Disagree1Strongly Disagree0At times, I think I am no good at all.Strongly Disagree0Disagree1Agree2Strongly Agree3I feel that I have a number of good qualities.Strongly Agree3Agree2Disagree1Strongly Disagree0I am able to do things as well as most other people.Strongly Agree3Agree2Disagree1Strongly Disagree0I feel I do not have much to be proud of.Strongly Disagree0Disagree1Agree2Strongly Agree3I certainly feel useless at times.Strongly Disagree0Disagree1Agree2Strongly Agree3I feel that I'm a person of worth, at least on an equal plane with others.Strongly Agree3Agree2Disagree1Strongly Disagree0I wish I could have more respect for myself.Strongly Disagree0Disagree1Agree2Strongly Agree3All in all, I am inclined to feel hat I am a failure.Strongly Disagree0Disagree1Agree2Strongly Agree3I take a Positive attitude to myselfStrongly Agree3Agree2Disagree1Strongly Disagree0**Total Score**30

CHU 9D {#Sec22}
------

This PRO was taken from the Child Health Utility 9D (CHU 9D) (UK weighted tariff) \[[@CR19]\], and was developed as a measure of a patient's health related quality of life. This PRO has a total of 9 domains with an individual domain scoring range of weightings ranging from 0 to 0.1079 when considering all domains collectively (Table 12 in [Appendix](#Sec13){ref-type="sec"}). The total scale scoring range from all domains is 0.33 to 1 where a higher score implies good health \[[@CR20]\].

Table 12CHU 9DCHU9DQuestionPossible AnswerScore of coded valueWorriedI don't feel worried today0I feel a little bit worried today0.0227I feel a bit worried today0.0227I feel quite worried today0.0227I feel very worried today0.0227SadI don't feel sad today0I feel a little bit sad today0.042I feel a bit sad today0.0445I feel quite sad today0.0722I feel very sad today0.0722PainI don't have any pain today0I don't have any pain today0.0322I don't have any pain today0.0322I don't have any pain today0.1245I don't have any pain today0.1426TiredI don't feel tired today0I feel a little bit tired today0.0479I feel a bit tired today0.0479I feel quite tired today0.0479I feel very tired today0.0479AnnoyedI don't feel annoyed today0I feel a little bit annoyed today0.0313I feel a bit annoyed today0.0313I feel quite annoyed today0.0313I feel very annoyed today0.0313School Work/ Homework (such as reading, writing, doing lessons)I have no problems with my schoolwork/homework today0I have a few problems with my schoolwork/homework today0.0487I have some problems with my schoolwork/homework today0.0487I have many problems with my schoolwork/homework today0.0656I can't do my schoolwork/homework today0.0656SleepLast night I had no problems sleeping0Last night I had a few problems sleeping0.0212Last night I had some problems sleeping0.0212Last night I had many problems sleeping0.0506Last night I couldn't sleep at all0.0907Daily routine (things like eating, having a bath/shower, getting dressed)I have no problems with my daily routine today0I have a few problems with my daily routine today0.0371I have some problems with my daily routine today0.0612I have many problems with my daily routine today0.0699I can't do my daily routine today0.093Able to join in activities (things like playing out with your friends, doing sports, joining in things)I can join in with any activities today0I can join in with most activities today0.0368I can join in with some activities today0.0368I can join in with a few activities today0.0368I can join in with no activities today0.1079

PedsQL™ Multidimensional Fatigue Scale {#Sec23}
--------------------------------------

This PRO taken from the PedsQL™ Multidimensional Fatigue Scale \[[@CR21]\] was used to measure the fatigue of the patients. This fatigue scale is formed of 18 items comprising of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items), and Cognitive Fatigue Scale (6 items) Each individual domain is scored from 0 to 100, where based on intrinsic calculations, the total scale scoring range is also 0--100, where a higher score implies less problems with fatigue (Good).

Patient Reporting and Timing {#Sec24}
----------------------------

Table 13PRO reporting timescalesPatient Reported Outcomes and Quality of Life ScalesTiming Schedule (Days)Tremor Impact Scale8Impact of Disease Scale28Impact on the family Scale28Wider impact Scale28Perceived Stress60Global Self Worth60Rosenberg Self Esteem60CHU9D60General Fatigue31Sleep/Rest Fatigue31Cognitive Fatigue31

ADE

:   Average daily steps per epoch

ADM

:   Average daily maximum

ADS

:   Average daily steps

BARS

:   Brief Ataxia Rating Scale

CHU 9D

:   Child Health Utility 9D

mPROs

:   Mobile Patient Reported Outcomes

6MWT

:   6-min walk test

SD

:   Sandhoff disease

TSD

:   Tay-Sachs disease
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